MA53550A - Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci - Google Patents
Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ciInfo
- Publication number
- MA53550A MA53550A MA053550A MA53550A MA53550A MA 53550 A MA53550 A MA 53550A MA 053550 A MA053550 A MA 053550A MA 53550 A MA53550 A MA 53550A MA 53550 A MA53550 A MA 53550A
- Authority
- MA
- Morocco
- Prior art keywords
- tubulysins
- intermediates
- preparation
- alternative methods
- alternative
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title 1
- 229930184737 tubulysin Natural products 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862728639P | 2018-09-07 | 2018-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53550A true MA53550A (fr) | 2021-12-15 |
Family
ID=68000124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053550A MA53550A (fr) | 2018-09-07 | 2019-09-06 | Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230002440A1 (enExample) |
| EP (1) | EP3847161A1 (enExample) |
| JP (1) | JP7511543B2 (enExample) |
| KR (1) | KR20210073525A (enExample) |
| CN (1) | CN112996778A (enExample) |
| AU (1) | AU2019336231A1 (enExample) |
| BR (1) | BR112021004317A2 (enExample) |
| CA (1) | CA3111149A1 (enExample) |
| EA (1) | EA202190699A1 (enExample) |
| IL (1) | IL281090A (enExample) |
| MA (1) | MA53550A (enExample) |
| MX (1) | MX2021002570A (enExample) |
| SA (1) | SA521421375B1 (enExample) |
| SG (1) | SG11202102126VA (enExample) |
| TW (1) | TWI825169B (enExample) |
| UA (1) | UA128730C2 (enExample) |
| WO (1) | WO2020051503A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020482800B2 (en) * | 2020-12-23 | 2025-08-21 | Genequantum Healthcare (Suzhou) Co., Ltd. | Novel isomeric compounds comprising a ring-opened thiosuccinimide group, an oligopeptide fragment and a chiral moiety |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2148886B1 (en) * | 2007-05-10 | 2014-02-19 | R & D Biopharmaceuticals Gmbh | Tubulysine derivatives |
| IT1394860B1 (it) | 2009-07-22 | 2012-07-20 | Kemotech S R L | Composti farmaceutici |
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| MA50124A (fr) * | 2017-09-08 | 2020-07-15 | Seattle Genetics Inc | Procédé de préparation de tubulysines et d'intermédiaires de celles-ci |
-
2019
- 2019-09-06 KR KR1020217010157A patent/KR20210073525A/ko not_active Withdrawn
- 2019-09-06 JP JP2021512696A patent/JP7511543B2/ja active Active
- 2019-09-06 US US17/273,693 patent/US20230002440A1/en not_active Abandoned
- 2019-09-06 MA MA053550A patent/MA53550A/fr unknown
- 2019-09-06 SG SG11202102126VA patent/SG11202102126VA/en unknown
- 2019-09-06 CN CN201980071734.XA patent/CN112996778A/zh active Pending
- 2019-09-06 MX MX2021002570A patent/MX2021002570A/es unknown
- 2019-09-06 AU AU2019336231A patent/AU2019336231A1/en not_active Abandoned
- 2019-09-06 EA EA202190699A patent/EA202190699A1/ru unknown
- 2019-09-06 BR BR112021004317-9A patent/BR112021004317A2/pt unknown
- 2019-09-06 WO PCT/US2019/050023 patent/WO2020051503A1/en not_active Ceased
- 2019-09-06 TW TW108132162A patent/TWI825169B/zh active
- 2019-09-06 EP EP19773284.5A patent/EP3847161A1/en active Pending
- 2019-09-06 UA UAA202101737A patent/UA128730C2/uk unknown
- 2019-09-06 CA CA3111149A patent/CA3111149A1/en active Pending
-
2021
- 2021-02-24 IL IL281090A patent/IL281090A/en unknown
- 2021-03-03 SA SA521421375A patent/SA521421375B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SA521421375B1 (ar) | 2024-02-11 |
| EP3847161A1 (en) | 2021-07-14 |
| EA202190699A1 (ru) | 2021-06-08 |
| CN112996778A (zh) | 2021-06-18 |
| JP7511543B2 (ja) | 2024-07-05 |
| TWI825169B (zh) | 2023-12-11 |
| WO2020051503A1 (en) | 2020-03-12 |
| KR20210073525A (ko) | 2021-06-18 |
| CA3111149A1 (en) | 2020-03-12 |
| US20230002440A1 (en) | 2023-01-05 |
| AU2019336231A1 (en) | 2021-03-18 |
| TW202024043A (zh) | 2020-07-01 |
| BR112021004317A2 (pt) | 2021-05-25 |
| JP2021536475A (ja) | 2021-12-27 |
| SG11202102126VA (en) | 2021-04-29 |
| IL281090A (en) | 2021-04-29 |
| UA128730C2 (uk) | 2024-10-09 |
| MX2021002570A (es) | 2021-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
| EP3893655A4 (en) | METHOD OF PREPARING A PLANT PROTEIN COMPOSITION | |
| MA53445A (fr) | Procédés et compositions pour la modification de plantes | |
| MA55082A (fr) | Compositions, procédés, et kits pour l'administration de polyribonucléotides | |
| EP3774709A4 (en) | METHOD FOR REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM USING INHIBITORS OF HIF-2-ALPHA | |
| MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
| EP3402483A4 (en) | METHOD AND COMPOSITIONS FOR ACTIVATING GAMMA DELTA T CELLS | |
| EP3328429A4 (en) | PEPTIDES AND ANTIBODIES FOR THE DISPOSAL OF BIOFILMS | |
| EP3891272A4 (en) | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | |
| EP3897717A4 (en) | METHODS FOR THE PRODUCTION OF HETERODIMERS ANTIBODIES | |
| EP3833340A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT FOR PRESBYOPIA | |
| EP3768281A4 (en) | COMPOSITIONS AND METHODS OF ACTIVATING T-CELLS AND CYTOKINES | |
| EP3450426A4 (en) | PROCESS FOR SYNTHESIS OF SILODOSINE AND INTERMEDIATE PRODUCT THEREOF | |
| EP3361864A4 (en) | DEVICES AND METHOD FOR PRODUCING A BIOLOGICAL SAMPLE FOR A CRYOPROCEDURE | |
| EP3648773A4 (en) | COMPOUNDS AND METHODS OF TRANSMEMBRANE DELIVERY OF MOLECULES | |
| MA46431A (fr) | Composés et procédés pour réduire l'expression de tau | |
| MA53370A (fr) | Procédé et intermédiaires pour la préparation de bilastine | |
| MA42497A (fr) | Procédés et compositions pour la régulation sélective de l'expression protéique | |
| MA51307A (fr) | Compositions laitières fermentées et procédés de préparation de celles-ci | |
| EP3902792A4 (en) | PROCESS FOR THE PREPARATION OF ANTHRANILAMIDES | |
| EP3867642A4 (en) | PROCEDURE FOR SCREENING OF UBIQUITIN LIGASE AGONISTS | |
| IL288090A (en) | Expression of antigen-binding proteins in the nervous system | |
| MA71753A (fr) | Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble | |
| EP3801485A4 (en) | PROTEIN AND PEPTIDE PURIFICATION PROCEDURES | |
| EP3679050A4 (en) | METHODS AND COMPOSITIONS FOR IMPROVED EXPRESSION OF RECOMBINANT PROTEINS |